Stay updated on Nivolumab and Brentuximab Vedotin in Older Hodgkin Lymphoma Clinical Trial

Sign up to get notified when there's something new on the Nivolumab and Brentuximab Vedotin in Older Hodgkin Lymphoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab and Brentuximab Vedotin in Older Hodgkin Lymphoma Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    The value 06 03 06 has recently changed to 24 22 (Estimated) 24. This change represents an update in the estimated study completion date for the phase II trial of nivolumab and brentuximab vedotin in treating older patients with untreated Hodgkin lymphoma.
    Difference
    0.3%
    Check dated 2024-05-25T08:34:24.000Z thumbnail image
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    Change Detected
    Summary
    The value of Participation Criteria 6 on the webpage has been updated to specify that researchers are looking for individuals with Classical Hodgkin lymphoma determined by local hematopathology review, aged 60 years or older, or those under 60 years but unsuitable for standard chemotherapy due to specific health conditions.
    Difference
    40%
    Check dated 2024-05-22T07:48:16.000Z thumbnail image
  5. Check
    5 days ago
    No Change Detected
  6. Check
    19 days ago
    Change Detected
    Summary
    The value (Estimated) on the webpage has recently changed to . This change likely indicates an update or modification in the estimated study completion date for the clinical trial involving nivolumab and brentuximab vedotin in treating older patients with untreated Hodgkin lymphoma.
    Difference
    0.0%
    Check dated 2024-05-07T16:24:57.000Z thumbnail image
  7. Check
    20 days ago
    Change Detected
    Summary
    The value 04 18 04 16 04 18 has recently changed to 05 06 05 03 (Estimated) 05 06. This change likely represents an update or modification in the data related to the efficacy or outcomes of the nivolumab and brentuximab vedotin treatment for older patients with untreated Hodgkin lymphoma in the clinical trial study.
    Difference
    0.5%
    Check dated 2024-05-06T14:41:32.000Z thumbnail image
  8. Check
    25 days ago
    Change Detected
    Difference
    0.8%
    Check dated 2024-04-30T21:58:42.000Z thumbnail image

Stay in the know with updates to Nivolumab and Brentuximab Vedotin in Older Hodgkin Lymphoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab and Brentuximab Vedotin in Older Hodgkin Lymphoma Clinical Trial page.